tirzepatide glaucoma Linked to Lower Risk in Type 2 Diabetes Compared to Other Weight Loss Drugs: Study One GLP-1 Drug May Be
Description
Why Choose Klinic in Murfreesboro for Tirzepatide Treatment
A separate retrospective study published in 2025 in JAMA Ophthalmology compared patients who took either oral or subcutaneous semaglutide for type 2 diabetes and matched them to control based on race, sex, A1c and comorbid conditions such as DR, sleep apnea, hypertension and hyperlipidemia
Reducing glucagon production
Before propensity score matching, the semaglutide or tirzepatide cohort and other GLP-1RA cohorts included 82 972 and 124 908 patients, respectively
Tirzepatide has a half-life of about 5 days, meaning it takes roughly 5 days for half the medication to leave your body
This large-scale analysis addressed that concern head-on
